Physician profile
Ronald Singal
NPI 1326028895
$2,350.06
in general payments reported to CMS, 2019-2025
18 companies · $230 in 2025
The $230 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $622 · 2020: $22.51 · 2021: $551 · 2022: $318 · 2023: $215 · 2024: $392 · 2025: $230.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $837.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $837.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $400.96 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $363.02 | 2021-2022 | |
| Alcon Vision LLC | $259.44 | 2024-2025 | Rocklatan, Rhopressa |
| Aerie Pharmaceuticals, INC. | $225.20 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $220.09 | 2019 | |
| Mallinckrodt Hospital Products INC. | $167.75 | 2022-2023 | Acthar |
| Horizon Therapeutics Plc | $154.93 | 2022-2023 | Tepezza |
| Bausch & Lomb Americas INC. | $103.74 | 2024-2025 | Miebo, Vyzulta, Envista Mx60 Iol |
| Dompe US, INC. | $96.28 | 2021-2025 | Oxervate |
| Abbvie INC. | $62.40 | 2023-2024 | Alphagan P, Lumigan, Vuity |
| Astellas Pharma US INC | $60.39 | 2024 | Izervay |
| Tarsus Pharmaceuticals, INC. | $55.91 | 2025 | Xdemvy |
| Amgen INC. | $47.76 | 2024 | Tepezza |
| Thea Pharma INC. | $35.09 | 2023 | |
| Shire North American Group INC | $34.58 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ocular Therapeutix, INC. | $23.66 | 2023 | Dextenza |
| Sun Pharmaceutical Industries INC. | $22.51 | 2020 | |
| Glaukos Corporation | $16.35 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Singal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.